BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:eloralintide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of eloralintide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07738614-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:eloralintide: Phase 1 readout est. (NCT07738614)
DESCRIPTION:eloralintide\, phase 1\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\nEstimated prima
 ry completion: December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07738614
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07401862-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:eloralintide: Phase 1 readout est. (NCT07401862)
DESCRIPTION:eloralintide\, phase 1.\nStudy: A Study of Eloralintide (LY3841
 136) in Participants With Different Levels of Liver Damage and in Particip
 ants With Healthy Livers.\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07401862
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215559-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:eloralintide: Phase 2 readout est. (NCT07215559)
DESCRIPTION:eloralintide\, phase 2\, Obesity.\nStudy: A Study of Macupatide
  (LY3532226) and Eloralintide (LY3841136)\, Alone or in Combination\, in A
 dults With Obesity or Overweight and With Type 2 Diabetes\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07215559
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935304-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:eloralintide: Phase 1 readout est. (NCT07935304)
DESCRIPTION:eloralintide\, phase 1.\nStudy: A Study Assessing Eloralintide 
 (LY3841136) in Healthy Participants\nEstimated primary completion: April 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793530
 4
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765511-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:eloralintide: Phase 1 readout est. (NCT07765511)
DESCRIPTION:eloralintide\, phase 1\, Obesity.\nStudy: A Study of Macupatide
  (LY3532226) in Participants With Obesity or Overweight Without Type 2 Dia
 betes\nEstimated primary completion: June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07765511
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808060-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:eloralintide: Phase 1 readout est. (NCT07808060)
DESCRIPTION:eloralintide\, phase 1\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Female Participants With Obesity or Overweight\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/eloralintide#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07808060
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665879-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:eloralintide: Phase 1 readout est. (NCT07665879)
DESCRIPTION:eloralintide\, phase 1\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Overweight or Obesity\nEstimated prima
 ry completion: August 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07665879
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06143956-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:eloralintide: Phase 2 readout est. (NCT06143956)
DESCRIPTION:eloralintide\, phase 2\, Obesity.\nStudy: A Master Protocol Stu
 dy (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult
  Participants With Obesity or Overweight\nEstimated primary completion: Se
 ptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elorali
 ntide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06143956
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589608-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:eloralintide: Phase 2 readout est. (NCT07589608)
DESCRIPTION:eloralintide\, phase 2\, Obesity.\nStudy: A Study to Investigat
 e Weight Management With Macupatide and Eloralintide\, Alone or in Combina
 tion\, in Adult Participants With Obesity or Overweight\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07589608
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282600-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07282600)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, and Type 2 Dia
 betes\nEstimated primary completion: January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07282600
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321886-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07321886)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity\, or Overweight Without Type 2
  Diabetes\nEstimated primary completion: March 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07321886
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369011-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07369011)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or
  Overweight\nEstimated primary completion: March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07369011
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353931-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:eloralintide: Phase 3 readout est. (NCT07353931)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: Efficacy and Safety o
 f Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain a
 nd Obesity or Overweight\nEstimated primary completion: March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07353931
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392190-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:eloralintide: Phase 3 readout est. (NCT07392190)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Persistent Obesity Who Are Treated Wit
 h a Weekly Incretin\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/eloralintide#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07392190
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881432-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:eloralintide: Phase 3 readout est. (NCT07881432)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of EloraTZP i
 n Adult Participants With Obesity Without Type 2 Diabetes\nEstimated prima
 ry completion: October 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/eloralintide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07881432
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07881458-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:eloralintide: Phase 3 readout est. (NCT07881458)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of EloraTZP i
 n Adult Participants With Obesity or Overweight and Type 2 Diabetes\nEstim
 ated primary completion: October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/eloralintide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07881458
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07900633-278@assetmemo.bio
DTSTAMP:20261121T004946Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:eloralintide: Phase 3 readout est. (NCT07900633)
DESCRIPTION:eloralintide\, phase 3\, Obesity.\nStudy: A Study of Eloralinti
 de (LY3841136) in Participants With Obesity or Overweight\, Type 2 Diabete
 s\, and Increased Cardiovascular Risk\nEstimated primary completion: Novem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eloralintid
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 900633
URL:https://assetmemo.bio/drug/eloralintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
